

## Republic of the Philippines PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City
Call Center: (02) 8441-7442 | Trunkline: (02) 8441-7444
www.philhealth.gov.ph



PHILHEALTH CIRCULAR No. 1011 - 000 7

TO

ALL PHILHEALTH MEMBERS, ACCREDITED HEALTH CARE

INSTITUTIONS/ PROVIDERS, PHILHEALTH REGIONAL OFFICES, BRANCHES, LOCAL HEALTH INSURANCE OFFICES

AND ALL OTHERS CONCERNED

SUBJECT

Guidelines on the COVID-19 Community Isolation Benefit Package

(CCIBP) (Revision 2)

### I. RATIONALE

In addressing the COVID-19 global pandemic, the President of the Philippines, through Republic Act 11469 (Bayanihan to Heal as One Act) and Presidential Proclamation No. 929 s.2020, declared a State of Public Health Emergency and subsequently imposed an Enhanced Community Quarantine (ECQ) throughout Luzon. In response, PhilHealth, through PhilHealth Board Resolution No. 2516 s. 2020, committed to develop benefit packages providing for health services, including community-based isolation, to all Filipinos affected by the COVID-19.

### II. OBJECTIVES

This *PhilHealth* Circular aims to provide coverage for all Filipinos for health services in identified Community Isolation Units (CIUs) for COVID-19. It aims to operationalize the PhilHealth COVID-19 Community Isolation Benefit Package (CCIBP) and provide specific guidelines for *accreditation*, benefit availment and applicable payment mechanism, reporting rules and performance assessment.

### III. SCOPE

This *PhilHealth* Circular shall apply to *accreditation and to* all claims for services provided by identified publicly or privately-run facilities temporarily serving as Community Isolation Units (CIUs) in response to the COVID-19 global pandemic.

### **DEFINITION OF TERMS**

- A. Case Investigation Form (CIF)<sup>1</sup> electronic reporting form specific for COVID-19 data that allows standard reporting of information for epidemiologic study and monitoring.
- B. Community Isolation Units (CIUs)<sup>2</sup>-a DOH certified publicly or privately owned non-

<sup>&</sup>lt;sup>1</sup> DOH- DILG Joint Administrative Order No. 2020-0001: Guidelines on Local Isolation and General Treatment Areas for COVID-19 cases (LIGTAS COVID) and the Community-based Management of Mild COVID-19 Cases



hospital facilities set-up in coordination with or by the national government (NG) or local government units (LGUs) to serve as quarantine facilities for COVID-19 cases, based on DOH guidelines. Examples of CIUs include LIGTAS COVID Centers and Mega LIGTAS COVID Centers.

- C. Free Standing Facility a facility that does not share basic services with a hospital-based provider.
- D. Isolation<sup>3</sup>- the separation of ill or infected persons from others to prevent the spread of infection or contamination.
- E. Local Isolation and General Treatment Areas for COVID-19 cases (LIGTAS COVID) center<sup>4</sup>- a community-managed facility within a barangay, municipality, city or province, where contact, suspect, probable, and confirmed cases of COVID-19 with mild symptoms, whose home environment cannot support physical distancing (e.g. crowded living conditions) can be temporarily housed for quarantine or isolation, which is linked to a health care institution (HCI) for referral purposes. A LIGTAS COVID Center is one type of Community Isolation Unit (CIU).
- F. Mega LIGTAS COVID Center<sup>5</sup>— larger scale versions of the LIGTAS COVID Center, managed by the national government and also referred to as Temporary Treatment and Monitoring Facilities (TTMF), operating at the provincial/regional level to supplement LIGTAS COVID Centers and properly refer patients to appropriate facilities in accordance with separate guidelines for the purpose to be issued by the DOH.

### V. POLICY STATEMENTS

- A. Accreditation of Community Isolation Units (CIUs) as Providers of the COVID-19 Community Isolation Benefit (CCIBP)
  - 1. CIUs shall either be:
    - a. Free standing facilities, including converted non-hospital facilities such as LIGTAS COVID and Mega LIGTAS COVID Centers, and level 1 (L1) hospitals, set up and managed by the local government unit (LGU) or national government (NG) linked to a PhilHealth accredited level 2 (L2) or level 3 (L3) referral hospital, or
    - b. Facilities set-up and managed by a publicly or privately owned L2 or L3 hospital in coordination with a LGU or the NG, provided that (1) there is no LGU or NG managed CIU in or nearby the municipality and/or (2) the LGU and/or NG recognizes the need and provides explicit permission for the L2 or L3 hospital to set-up a CIU.
  - 2. In order to be eligible to provide the CCIBP, CIUs must be certified by DOH and accredited by PhilHealth.
  - 3. All CIUs seeking accreditation shall establish referral arrangements with a higher-level facility. CIUs shall be allowed to declare only Philhealth accredited L2 or L3 hospitals as referral facilities. Referral facilities shall provide technical support and shall service

<sup>2</sup> ibid

<sup>3</sup> ibid

4 ibid

5 ibid



patients needing endorsement to a higher-level facility as defined in applicable DOH guidelines.

- 4. All public and private facilities certified by the DOH as CIUs shall be deemed accredited by Phill-lealth for the COVID-19 Community Isolation Benefit Package (CCIBP), provided they submit to Phill-lealth the following:\*
  - a. Proof of DOH certification or inclusion in the list of DOH certified CIUs from Center for Health Development;
  - b. Provider Data Record (see Annex A);
  - c. Signed performance commitment (see Annex B);
  - d. Supplemental Provider Data Record (see Annex C)\*\*
  - e. Authorization from PhilHealth accredited partner facilities with eClaim system such as MCP, TB-DOTS, hospitals, for electronic claims submission and reimbursement arrangements (see part II of Annex C).
  - \* These documents shall be required for submission during application for initial, renewal and reaccreditation.
  - \*\* Supplemental PDR shall be submitted after approval of initial accreditation prior to the release of their reimbursements and when there is/ are change/s in the auto credit payment system (ACPS).
- 5. Different variations of ownership and management arrangements in setting up the CIU (see Annex D) shall be permitted provided that:
  - a. the CIU facility and its designated manager is clearly identified;
  - b. the CIU and its partners have an agreement to file and submit claims and receive claim payments electronically in a way that is consistent with existing PhilHealth guidelines and procedures, and;
  - c. the CIU and its partners have an agreement for referral arrangements.

### B. Benefit Package

- 1. The COVID-19 Community Isolation Benefit Package (CCIBP) shall include all identified services needed to effectively manage cases needing isolation, based on applicable guidelines adopted by DOH (see Annex E), whether suspect, probable, confirmed or mild (see Annex F).
- 2. Standards for these health services shall be in accordance with the applicable guidelines set forth by the DOH. The benefit package shall be updated as needed to reflect current protocols and standards in collaboration with relevant institutions, experts and stakeholders.
- 3. The package shall cover all inputs and activities within the entire episode of care at the CIU including payment for staff and professional fees, medicine, diagnostics, transport and other operational cost.
- 4. Testing and inpatient services for COVID-19 patients shall be covered by other applicable COVID-19 case rates.

### C. Availment of the Benefit Package for Community Isolation

- 1. Criteria for availment of the package:
  - a. PhilHealth beneficiaries registered under the National Health Insurance Program (NHIP) who meet the clinical and/or social criteria (see Annex G) as stated in the applicable DOH issuances for community isolation shall be eligible to avail of the package.



1000



- b. Filipinos who are not yet registered under the program shall automatically be covered, provided that they complete and submit an accomplished PhilHealth Member Registration Form (PMRF) for the issuance of the PIN or inclusion of the dependent upon availing of the benefit package. The patient, through the provider, shall submit the accomplished PMRF within the period of isolation in accordance with the rules on immediate eligibility defined in PhilHealth Circular No. 2019-0010.
- c. Eligibility to the benefit package of a non-Filipino member or dependent shall be in accordance with the existing guidelines on the enrollment of foreign nationals whether employed or under the informal economy program.

### 2. Package Rate and Rules on Co-pay (see Annex H)

The package shall be paid as a case rate in the amount of Php 22,449.00. Any modifications in the package rate shall be released through a PhilHealth Advisory.

3. Claims Filing and Reimbursement

- a. Whenever applicable, the CIU, through its partner facility, can file a claim using the e-Claim system for patients who were discharged after providing all mandatory services (see Annex E). Claims for testing for SARS-CoV-2 *shall be filed in* accordance to PhilHealth Circular on COVID-19 testing.
- b. All claim application shall include the following:
  - b.1. Claim Form 2 (CF2)
  - b.2. Case Investigation Form or CIF (see Annex I)
  - b.3. Accomplished Claim Signature Form (CSF).
- c. Direct filing of claims by beneficiaries shall not be allowed.
- d. All claims submitted by the accredited CIU shall be processed by PhilHealth within sixty (60) calendar days from receipt of claim provided that all requirements are fulfilled.
- e. Claims shall be filed within 60 calendar days upon discharge of the patients. Existing rules on the late filing of claims shall apply.
- f. Claims with incomplete requirements/discrepancy/ies shall be returned to sender (RTS) for compliance within 60 calendar days from receipt of notice.
- g. The accredited CIU may apply for motion for reconsideration for all denied claims based on existing PhilHealth policies.
- h. In the event of the clinical deterioration of the patient, the CIU must follow the guidelines on patient transfer that have been set forth by the DOH. The accredited CIU may still file a claim for the services rendered to the patient.
- i. All claims filed for patients needing readmission to the CIU facility after discharge from an inpatient facility in accordance with DOH guidelines shall be filed as a new claim.
- j. In the event that the patient expires in the course of isolation, the accredited CIU may still file a claim for the CCIBP package.
- k. Converted non-hospital CIUs such as those identified as LIGTAS COVID and Mega LIGTAS COVID centers shall not be allowed to file for other case rates apart from CCIBP. Accredited hospitals and free standing facilities that are also DOH certified CIUs shall be allowed to continue to file claims for other case rates based on existing PhilHealth policies.
- 1. Claims shall be paid to the CIU or through its partner facility if applicable.
- m. Payments for services rendered and applicable payment terms, whether for claims processing and/or diagnostics and commodities support, shall be negotiated and settled between the CIU and its partner facilities.
- n. PhilHealth shall not prescribe a provider-facility share nor recommend charging



rules for claims processing, for diagnostics and commodities support, and/or for any other shared costs between CIUs and their partner facilities.

### D. MONITORING AND EVALUATION

The PhilHealth, through its Healthcare Provider Performance Assessment System (HCP-PAS) shall employ mechanisms to assure members of the guaranteed quality healthcare they deserve.

A monitoring and feedback system shall be implemented to assist providers to identify possible gaps in their practices or recommend mechanisms to ensure that they render the best possible service to their clients.

PhilHealth shall conduct a periodic review of this policy and specific provisions shall be revised as needed. The review shall require the monthly submission of relevant documents including but not limited to, expenditure and utilization report (see Annex J) and the list of the admitted patients (see Annex K).

CIUs shall ensure that the patient medical record or chart inclusive of admitting history, CIF, patient monitoring sheet, and administered medication, shall be made available upon the behest of PhilHealth.

### E. ANNEXES (to be posted in PhilHealth website)

Annex A: Provider Data Record

Annex B: Performance Commitment

Annex C: Supplemental Provider Data Record

Annex D: Possible Scenarios in Terms of CIU Management and Ownership

Annex E: Mandatory and Other Health Services

Annex F: Definition of Eligible Cases for Isolation

Annex G: Clinical and/or Social Criteria

Annex H: Package Rate and Rules on Co-pay

Annex I: Case Investigation Form

Annex J: Expenditure and Utilization Report

Annex K: List of Admitted Patients

### VI. PENALTY CLAUSE

Any violation of this *PhilHealth* Circular, terms and conditions of the Performance Commitment, and all existing related PhilHealth Circulars and directives shall be dealt with accordingly.

### VII. SEPARABILITY CLAUSE

If any of the provision of this PhilHealth Circular shall be declared invalid, unconstitutional, or unenforceable, the validity of the remaining provisions shall not in any way be affected and shall remain enforceable.



Page 5 of 6

### VIII. REPEALING CLAUSE

This policy revises the following PhilHealth Circulars:

- A. Repeals PhilHealth Circular No. 2020-0012 "Guidelines On The COVID-19 Community Isolation
  Benefit Package (CCIBP)"
- B. Repeals PhilHealth Circular No. 2020-0018 "Guidelines On The COVID-19 Community Isolation Benefit Package (CCIBP) Revision 1"
- C. Repeals PhilHealth Circular No. 2021-0024 "Modification On The Minimum Length Of Stay (LOS) In PhilHealth Accredited Community Isolations Units (CIU)"

#### IX. DATE OF EFFECTIVITY

The PhilHealth Circular shall take effect immediately after publication in any newspaper of general circulation or Official Gazette. A copy thereof shall be deposited thereafter with the Office of the National Administrative Register at the University of the Philippines Law Center.

ATTY. DANTE A. GIERRAN, CPA, President and Chief Executive Officer (CEO)

Date signed: 13 April 2022







Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION
City State Bldg., 709 Shaw Blvd., Pasig City
Health Line 441-7444; www.philhealth.gov.ph



### PROVIDER DATA RECORD **HEALTH CARE INSTITUTION**

THE PRESIDENT Philippine Health I	nsurance Corp	poration							
Pasig City, Philipp Sir/Madam: I,				, of le	gal age, _				with
							(Positio	on/Designation)	
in behalf of								ized representative to act for he following pertinent	ranu
information and do amended by RA 1 Name of Health	0606.		Sec. 56 of	f the Implem	enting Rule	s and Regu	ulations of		
A 194 11 A1 1						Incorporate	u. F1		
Accreditation Numb						PhilHeal	in Employe	er Number	
Mailing/Billing No./St./Brgy.	Address:		_						
Municipality /City	-			Province	e:			ZIP Code	
Contact Inform		Fax No.		069-14	al Empil Ada	iress: (man	datasil	<u>-</u>	-
Centact Nn		Pax No		United	ai Fmail Add	iress iman	natoryj		
Facility Head/ N	ledical Dire	ctor/Chief of He	ospital/H	ospital Adı	ministrate	or	Accr	editation No.	
Contact Informat	ion of the Fac	ility Head:							
Contact Number							Fmai	Address	
A. Hospital: General Specialty DOH-LTO N	,	pital Level:	Level 1	v of DOH-LTC	Level 2		Leve	əl 3	_
DOH-LTO No * Validity of DO  Specialized 0	ient Beds* nary/Dispensar ing Homes *  DH-LTO  Outpatient Factory Surgical Clir	cility	Ani Ani	Outpatient P ti TB/DOTS F tternity Care I mary Care B Outpatien imal Bite Pac	Package ** Package (Menefit (PCB) t Malaria kage ** _ anding Dialy	CP)	DC)*	MCP, DOTS** and PCI MCP and DOTS** MCP and PCB PCB and DOTS**	В
DND / DO State Uni Others	· DOH retained )J tversities / Coll	ege P	rovince funicipality City District		Partner Corpora	ation (Specify)		Foundation Cooperative Civic organization	
	incumbent LC	oco obcols\			name of ow	ner/s			
Type of Application Initial Application Continuous Re-accredit	cation Accreditation	Chá Upọ Add	nsfer of loca ange in faci grading of h ditional serv	ation lity classificat lospital level rice operation after			accreditat Previous Co The Update hange in Fa hange in na	after incurring a gap in tion regardless of length of gap ontinuous Accreditation was with a cility Head/ Medical director/ Coacility Head/ Medical director/ Co	
For PhilHealth	Use Only								
Date Received: L	HIO PRO HIO		By: By:	LHIO PRO LHIO PRO			Г	Control No.	<u>-</u>
Date Encoded:	'KO .HIO/PRO (Receiv PRO (Data Entry)	ina Module)	Ву:	LHIO PRO				Date Paid:	<u>-</u>

PC for CIUs April 2020

### (Letterhead of Healthcare Provider)

(Date) **PHILIPPINE HEALTH INSURANCE CORPORATION**17th Flr., City State Centre Bldg.,

Shaw Blvd., Pasig City

SUBJECT: Performance Commitment for Community Isolation Units

### Sir/Madam:

To guarantee our commitment to the National Health Insurance Program (NHIP), we respectfully submit this Performance Commitment.

And for the purposes of this Performance Commitment, we hereby warrant the following representations:

### A. REPRESENTATION OF ELIGIBILITIES


1.	That we are a duly DOH certified health care facility capable of delivering the services expected from the type of healthcare provider that we are applying for.
2.	That we are owned by
	and managed by and doing business under the name of
	with License/Certificate No
3.	That all professional health care providers in our facility, as applicable, are PhilHealth

3. That all professional health care providers in our facility, as applicable, are PhilHealth accredited, possess proper credentials and given appropriate privileges in accordance with our policies and procedures.

### B. COMPLIANCE TO PERTINENT LAWS/RULES & REGULATIONS/ POLICIES/ADMINISTRATIVE ORDERS AND ISSUANCES

Further, we hereby commit ourselves to the following:

- 3. That our officers, employees, and other personnel are members in good standing of the NHIP.
- 4. That, as responsible owner(s) and/or manager(s) of the institution, we shall be jointly and severally liable for all violations committed against the provisions of Rep. Act No. 7875, as amended, including its Implementing Rules and Regulations (IRR) and PhilHealth policies issued pursuant thereto.
- 5. That we shall promptly inform PhilHealth prior to any change in the ownership and/or management of our institution.



- 6. That any change in ownership and/or management of our institution shall not operate to exempt the previous and/or present owner and/or manager from liabilities for violations of Rep. Act No. 7875, as amended, and its IRR
- 7. That we shall maintain active membership in the NHIP as an employer not only during the entire validity of our participation in the NHIP as a Health Care Institution (HCI) but also during the corporate existence of our institution.
- 8. That we shall abide with all the implementing rules and regulations, memorandum circulars, special orders, advisories and other administrative issuances by PhilHealth affecting us.
- 9. That we shall abide with all administrative orders, circulars and such other policies, rules and regulations issued by the Department of Health and all other related government agencies and instrumentalities governing the operations of HCIs in participating in the NHIP.
- 10. That we shall adhere to pertinent statutory laws affecting the operations of HCIs including but not limited to the Senior Citizens Act (R.A.10645), the Breastfeeding Act (R.A. 7600), the Newborn Screening Act (R.A. 9288), the Cheaper Medicines Act (R.A. 9502), the Pharmacy Law (R.A. 5921), the Magna Carta for Disabled Persons (R.A. 9442), and all other laws, rules and regulations that may hereafter be passed by the Congress of the Philippines or any other authorized instrumentalities of the government.
- 11. That we shall promptly submit reports as may be required by PhilHealth, DOH and all other government agencies and instrumentalities governing the operations of HCIs.
- 12. That we shall facilitate distribution of the professional fee component of the PhilHealth payment/reimbursement to the concerned professionals not exceeding thirty (30) calendar days upon receipt of the reimbursement or at a time frame as agreed upon by the HCI and their professionals.
- 13. That being a government-owned (for public-owned facilities only) health care institution, we shall maintain a trust fund for the PhilHealth reimbursements in compliance to Section 34-A of Republic Act 10606 which provides that "revenues shall be used to defray operating costs other than salaries, to maintain or upgrade equipment, plant or facility, and to maintain or improve the quality of care.

# C. CONDUCT OF CLINICAL SERVICES, RECORDS, PREPARATION OF CLAIMS AND UNDERTAKINGS OF PARTICIPATION IN THE NHIP

- 14. That we are duly capable of delivering the CCIBP services for the duration of the validity of this commitment.
- 15. That we shall provide and charge to the PhilHealth benefit of the client the necessary services including but not limited to drugs, medicines, supplies, devices, and diagnostic and treatment procedures for our PhilHealth clients.
- 16. That we, being an accredited government hospital or infirmary/ASC/FDC/MCP/TB DOTS/ Animal Bite package/ DRTC/PCB and/or contracted provider for the Z benefit package provider, as applicable, shall provide the necessary drugs, supplies and services with no out-of-pocket expenses on the part of the qualified PhilHealth member and their dependents admitted or who consulted in the HCI, as mandated by the PhilHealth "No Balance Billing (NBB) Policy"



- 17. That we, being an accredited provider, shall abide by the rules set in the CCIBP, including the prescribed disposition of the PhilHealth reimbursements, as stated in the current guidelines, which shall be used by the HCI to be able to provide the mandatory services and ensure better health outcomes.
- 18. That we shall maintain a high level of service satisfaction among PhilHealth clients including all their qualified dependents/beneficiaries.
- 19. That we shall be guided by PhilHealth-approved clinical practice guidelines or if not available, other established and accepted standards of practice.
- 20. That we shall provide a PhilHealth Bulletin Board for the posting of updated information of the NHIP (circulars, memoranda, IEC materials, price reference index, etc.) in conspicuous places accessible to patients, members and dependents of the NHIP within our health facility.
- 21. That we shall always make available the necessary forms for PhilHealth member-patient's use.
- 22. That we shall treat PhilHealth member-patient with utmost courtesy and respect, assist them in availing PhilHealth benefits and provide them with accurate information on PhilHealth policies and guidelines.
- 23. That we shall ensure that PhilHealth member-patient with needs beyond our service capability are referred to appropriate PhilHealth-accredited health facilities.

### D.MANAGEMENT INFORMATION SYSTEM

- 24. That we shall maintain a registry of all our PhilHealth members-patients (including newborns) and a database of all claims filed containing actual charges (board, drugs, labs, auxiliary, services and professional fees), actual amount deducted by the facility as PhilHealth reimbursement and actual PhilHealth reimbursement, which shall be made available to PhilHealth or any of its authorized personnel.
- 25. That we shall maintain and submit to PhilHealth an electronic registry of physicians and dentists including their fields of practice, official e-mail and mobile phone numbers.
- 26. That we shall, if connected with e-claims, electronically encode the laboratory / diagnostic examinations done, drugs and supplies used in the care of the patient in our information system which shall be made available for PhilHealth use.
- 27. That we shall ensure that true and accurate data are encoded in all patients' records.
- 28. That we shall only file true and legitimate claims recognizing the period of filing the same after the patient's discharge as prescribed in PhilHealth circulars.
- 29. That we shall submit claims in the format required by PhilHealth for our facility.
- 30. That we shall regularly submit PhilHealth monitoring reports as required in PhilHealth circulars.

VE. REGULAR SURVEYS / ADMINISTRATIVE INVESTIGATIONS/DOMICILIARY
VISITATIONS ON THE CONDUCT OF OPERATIONS IN THE EXERCISE OF
THE PRIVILEGE OF ACCREDITATION

DC: MS Date: 4/9/22

.... - y ...

- 31. That we shall extend full cooperation with duly recognized authorities of PhilHealth and any other authorized personnel and instrumentalities to provide access to patient records and submit to any orderly assessment conducted by PhilHealth relative to any findings, adverse reports, pattern of utilization and/or any other acts indicative of any illegal, irregular and/or unethical practices in our operations as an accredited HCI of the NHIP that may be prejudicial or tends to undermine the NHIP and make available all pertinent official records and documents including the provision of copies thereof; provided that our rights to private ownership and privacy are respected at all times.
- 32. That we shall ensure that our officers, employees and personnel extend full cooperation and due courtesy to all PhilHealth officers, employees and staff during the conduct of assessment/visitation/investigation/monitoring of our operations as an accredited HCI of the NHIP.
- 33. That at any time during the period of our participation in the NHIP, upon request of PhilHealth, we shall voluntarily sign and execute a new 'Performance Commitment' to cover the remaining portion of our accreditation or to renew our participation with the NHIP as the case may be, as a sign of our good faith and continuous commitment to support the NHIP.
- 34. That, unless proven to be a palpable mistake or excusable error, we shall take full responsibility for any inaccuracies and/or falsities entered into and/or reflected in our patients' records as well as in any omission, addition, inaccuracies and/or falsities entered into and/or reflected in claims submitted to PhilHealth by our institution.
- 35. That we shall comply with PhilHealth's summons, subpoena, subpoena 'duces tecum' and other legal or quality assurance processes and requirements.
- 36. That we shall recognize the authority of PhilHealth, its Officers and personnel and/or its duly authorized representatives to conduct regular surveys, domiciliary visits, and/or conduct administrative assessments at any reasonable time relative to the exercise of our privilege and conduct of our operations as an accredited HCI of the NHIP.
- 37. That we shall comply with PhilHealth corrective actions given after monitoring activities within the prescribed period.

### F. MISCELLANEOUS PROVISIONS

- 38. That we shall protect the NHIP against abuse, violation and/or over-utilization of its funds and we shall not allow our institution to be a party to any act, scheme, plan, or contract that may directly or indirectly be prejudicial or detrimental to the NHIP.
- 39. That we shall not directly or indirectly engage in any form of unethical or improper practices as an accredited health care provider such as but not limited to solicitation of patients for purposes of compensability under the NHIP, the purpose and/or the end consideration of which tends unnecessary financial gain rather than promotion of the NHIP.
- 40. That we shall immediately report to PhilHealth, its Officers and/or to any of its personnel, any act of illegal, improper and/or unethical practices of HCI of the NHIP that may have come to our knowledge directly or indirectly.
- 41. That we shall allow PhilHealth to deduct or charge to our future claims, all reimbursements paid to our institution under the following, but not limited to: (a) during the period of its non-accredited status as a result of a gap in validity of our DOH LTO, suspension of

accreditation, etc; (2)downgrading of level, loss of license for certain services; (c)when NBB eligible PhilHealth members and their dependents were made to pay out-of-pocket for HCI and professional fees, if applicable; (d) validated claims of under deduction of PhilHealth benefits.

Furthermore, recognizing and respecting its indispensable role in the NHIP, we hereby acknowledge the power and authority of PhilHealth to do the following:

- 42. After due process and in accordance with the pertinent provisions of R.A. 7875 and its IRR, to suspend, shorten, pre-terminate and/or revoke our privilege of participating in the NHIP including the appurtenant benefits and opportunities at any time during the validity of the commitment for any violation of any provision of this Performance Commitment and of R.A. 7875, as amended, and its IRR.
- 43. After due process and in accordance with the pertinent provisions of R.A. 7875 and its IRR, to suspend, shorten, pre-terminate and/or revoke our accreditation including the appurtenant benefits and opportunities incident thereto at any time during the term of the commitment due to verified adverse reports/findings of pattern or any other similar incidents which may be indicative of any illegal, irregular or improper and/or unethical conduct of our operations.

We commit to extend our full support in sharing PhilHealth's vision in achieving this noble objective of providing accessible quality health insurance coverage for all Filipinos.

Very truly yours,

Head of Facility/Medical Director/ Chief of Hospital/ Medical Center Chief

With my express conformity,

Local Chief Executive (if LGU-owned)/Owner



* *	Part I - General II	-fa-maetan	<del> </del>
Name of Facility:	ran r- General n	поннацон	
Address	<u>-</u>		<del>-</del>
Address line 1:	· · · · ·	·	
Address line 2:			<del></del>
City/Municipality:		Province:	<del></del>
Region:			tal Code:
Mobile No.:		Landline No	
Email Address:		Landinie 140	(Office):
CIU Manager	<u> </u>	<del></del>	<del>_</del>
Last Name:		Maal	E Initials:
-		IVIICUE	
First Name:			Suffix:
	tional Affiliation:		
Position:			<u> </u>
Catchment			
No. of Muni	cipalities catered:	<u>.</u>	
Names of Municipalities catered:	<u> </u>	<del></del>	
			-
Referral Hospital 1	_		
Name of Facility		<del>_</del>	· -
Address line 1:			<del></del>
Address line 2:			
City/Municipality:		Province:	
Region:			tal Code:
	/ A 'F 13'-1 . 1 . F		tal Code:
Referral Hospital 2 (indicated N	A if no additional referra	u nospitalj	<del></del>
Name of Facility			
Address line 1:			
Address line 2:	<u> </u>	T D	<del></del>
City/Municipality:		Province:	10.1
Region: Referral Hospital 3 (indicated N	/		tal Code:
	/ A ir no additional referra	u nospitalj	
Name of Facility Address line 1:		<del></del>	<del></del>
Address line 1:		<del></del>	<del></del> -
City/Municipality:	<u> </u>	Province:	-10-1
Region:	<u> </u>		tal Code:
In cases where there are more than	n 3 referral hospitals, plea	se attach another for	m and fill out the "refer all
hospital" section.	0		
	Service Cap	acity	<u> </u>
Accommodations			<u>-</u>
Ward type:	tras accommodations.		<u> </u>
	type accommodations: for patients in ward type	accommodations.	
	for patients in ward type		<del></del> -
	for patients in ward type		<del></del>
	cohorting for patients in v		a (V/N).
Single Room:	concreting for patients in v	varu accommiouauom	D (1/11):
	oms w/o ensuite bathroo	me•	
	oms with ensuite bathroo		
Human Resource	OHS WITH CHSUIC DAILING	ills.	
	of employed physicians:	<del></del>	
	physicians on duty/day:		
	io. of employed nurses:		<del></del>
	of nurses on duty/day:		<u> </u>
	alth workers employed:		
List other types of health workers			
			·
Total no of other n	on-health workers emplo	ved.	
List other types of non-health wor		,····	
I certify that the information subm		true and correct to	the hest of my knowledge
	statements may result in		



For CIUS set up by Level 2 and Level 3 Hospitals

Further, in signing this document, I confirm that I have coordinated and secured explicit permission from LGUs of the municipality/municipalities identified above to serve as a CIU catering to their constituency.

### Part II - Authorization

This is to authorize (Name of the CIU facility) to use our eClaim system for the filing and submission of Covid-19 Community Isolation Benefit Package (CCIBP) claims using its own Phill-lealth Accreditation Number (PAN) and cipher key. Further, all Phill-lealth reimbursements for the CIU's filed claims shall be credited to the (name of partner institution) ACPS account and shall subsequently be disbursed to the said CIU based on agreed terms.

For this purpose, I hereby submit the following bank account information:

-

(Partner Facility)

7. Mobile Number

Signature over printed Name Medical Director/Authorized Representative

MASTER COPY COPY DOC: 14/9/20

### Annex D: Possible Scenarios in Terms of CIU Management and Ownership

Scenario:	Partner Facilities:
Managed: LGU Owned: LGU/Private Type of CIU: L1 Hospital	For Referral: L2 or L3 referral Hospital
Managed: LGU Owned: LGU/Private Type of CIU: Converted non-hospital facility*	For Claims Filing: PhilHealth accredited facilities such as MCP, TB-DOTS, Animal Bite, Hospital  For Commodities support: LGU-owned or Private L1 Hospital, or L2 or L3 referral
	For Referral: L2 or L3 referral Hospital
Managed: NG Owned: LGU/NG/Private Type of CIU: Converted non-hospital facility	For Claims Filing: PhilHealth accredited facilities such as MCP, TB-DOTS, Animal Bite, Hospital  For Commodities support: LGU-owned or Private L1 Hospital, or L2 or L3 referral
	For Referral: L2 or L3 referral Hospital
Managed: Private Hospital or Institution** Owned: LGU/NG/Private Type of CIU: L1 Hospital	For Referral: L2 or L3 referral Hospital
Managed: Private Hospital or Institution Owned: LGU/NG/Private Type of CIU: Converted non-hospital facility	For Claims Filing: PhilHealth accredited facilities such as MCP, TB-DOTS, Animal Bite, Hospital  For Commodities support: LGU-owned or Private L1 Hospital, or L2 or L3 referral
	For Referral: L2 or L3 referral Hospital

\*if the CIU is a non-hospital facility and the partner facility is L1 and owned by a different LGU, it cannot be engaged for purposes outside diagnostic and commodities support which shall be allowed only in extraneous circumstances where, for whatever reason, the LGU cannot anymore provide the logistical requirements needed to run its own CIU.

if a CIU is managed by a privately owned hospital or institution, the CIU shall be accredited to provide the benefit if (1) there is no LGU or NG managed CIU in the immediate vicinity and/or (2) the LGU and/or the NG recognizes the need to set up a CIU and provided explicit permission if or the privately-owned hospital to set-up a CIU in its behalf.

### Annex E: Mandatory and Other Health Services

	Mandatory Service	Other Service (as needed)	
a.	Minimum days of admission* (see below Table 1 COVID-19 Isolation Requirement Matrix) based on DOH applicable guidelines.	a. Drugs and Medicines, as specified in the applicable DOH policies.      b. Diagnostic Tests and Imaging, as	
	Boarding, food and individual hygiene kit Information and Education about respiratory etiquette and self- monitoring	specified in the applicable DOH policies.  c. Oxygen Support	
d.	Monitoring by a Health Care Professional	d. Referral and transportation to higher level facility	
mort	cept in case of transfer due to deterioration or ality based on discharge criteria from cable guidelines adopted by DOH.		

Table 1. COVID-19 Isolation Requirement Matrix

		Health Care Worker	Non-Health Care Worker
Vaccine	With Booster*	5 days	7 days
Status	Full	7 days	7 days
	Partial/Unvaccinated	10 days	10 days

<sup>\*</sup>Please indicate in the Case Investigation Form (CIF)

### Based on currently acceptable guidelines and other references including:

- Department of Health Department Memorandum 2022-0013: Updated Guidelines on Quarantine, Isolation, and Testing for COVID-19 response and Case Management for the Omicron Variant
- Department of Health Department Circular 2022-0002: Advisory on Covid-19 Protocols for Quarantine and Isolation
- Department of Health Department Memorandum 2020-0512: Revised Omnibus Interim Guidelines on Prevention, Detection, Isolation, Treatment, and Reintegration Strategies for COVID-19




## Annex F: Definition of Eligible Cases for Isolation

	8
CASES	
Suspect Case	Refers to:
	1. Suspect Criteria A - refers to a person who meets the clinical AND epidemiological criteria:
	a. Clinical criteria:
	i. Acute onset of fever AND cough; OR  ii. Acute onset of ANY THREE OR MORE of the following signs of symptoms: fever, cough, general weakness/fatigue, headache, myalgia, son throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mento status AND
	b. Epidemiological Criteria:
	i. Residing or working in an area with a high risk of transmission of viru.  closed residential settings, humanitarian settings such as camp and camp-lik  settings for displaced persons; anytime within the fourteen (14) days prior to  symptom onset; or  ii. Residing or travel to an area with community transmission anytime within
	the fourteen (14) days prior to symptom onset; or iii. Working in any health care setting, including within health facilities of within the community; any time within the fourteen (14) days prior is symptom onset.
	2. Suspect Criteria B - refers to a patient with Severe Acute Respiratory Illness (SARI acute respiratory infection with history of fever or measured fever of > 38C°; and cough with onset within the last ten (10) days; and requires hospitalization. A person who meet the clinical AND epidemiological criteria:
	3. Suspect Criteria C - refers to an asymptomatic person not meeting epidemiolog criteria with a POSITIVE SARS-CoV-2 Antigen-RDT
Probable Case	Refers to:
	1. A patient who meets clinical criteria AND is a contact of a probable or
	confirmed case or linked to a COVID-19 cluster; or  2. A suspect case with chest imaging showing findings suggestive of COVID-19
	disease; 3. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in
	the absence of any other identified cause;
	4. Death, not otherwise explained, in an adult with respiratory distress preceding death; AND was a contact of a probable or confirmed case or linked to a COVID-19 cluster.
Confirmed Case	Refers to any individual, irrespective of presence or absence of clinical signs and symptom who was laboratory confirmed for COVID-19 in a test conducted at the national referent laboratory, a subnational reference laboratory, and/or DOH-licensed COVID-19 testing laboratory; OR
Ď	any suspect or probable COVID-19 cases, who tested positive using antigen tests in area with outbreaks and/or in remote settings where RT-PCR is not immediately available.

3, 200

	provided that the antigen tests satisfy the recommended minimum regulatory, technical and operational specifications set by Health Technology Assessment Council
Mild COVID- 19	<ul> <li>No pneumonia or desaturation COVID-19</li> <li>Acute onset of fever and cough or any three (3) or more of the following: <ul> <li>Fever</li> <li>Cough</li> <li>Coryza</li> <li>Sore throat</li> <li>Diarrhea</li> <li>Anorexia/nausea/vomiting</li> <li>Loss of sense of smell or taste</li> <li>General weakness/body malaise/fatigue</li> <li>Headache</li> <li>Myalgia</li> </ul> </li> </ul>

Source: Annex B of Department of Health Department Circular No. 2022-0002: Advisory on Protocols for Quarantine and Isolation, January 6, 2022



J. 4. F. 18. 18


### . Clinical and Social Criteria based on Joint Administrative Order

ANNEX A. COVID-19 Patient Algorithm for Triage and Hospitalization (C-PATH).

Note: The DOH may henceforth release an updated version, which shall be used for this Order.

## FIGURE 1A. CLASSIFICATION OF CASES

Version 05 April 2020 (original)



2




4. Other situations as indicated by local risk assessments

second to box 10 if secons test becomes possible/available

Probable Case

## FIGURE 1B. CONTACT TRACING PROTOCOL

Version 06 April 2020 (original)



### FOOTNOTES

Exposure by travel

Travel from a country/area where there is sustained community level transmission

Exposure by residence

Lives in an LGU where there is sustained community level transmission-

Exposure by contact

- 1. Providing direct care to suspect, probable, or confirmed COVID-19 patients without using proper PPE (i.e. healthcare workers);
- 2. Face-10-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes:
- 3. Direct physical contact with a probable or confirmed case; OR
- 4. Other situations as indicated by local risk assessments

Acute Respiratory Illness (ARI)


Flu-like symptoms (cough, colds, sore throat, body malaise; fatigue,; fever)

Home Quarantine - All members of the household (including pets) must strictly stay at home

BHERT Monitoring


Barangay Health Emergency Response Team (BHERT)

- Accomplish a Case Identification Form (CIF)
- Ensure monitoring throughout the duration of isolation & quarantine
- · Facilitate home care and basic needs
- A daily report shall be forwarded to the Municipality/City
   Epidemiology and Surveillance Units (MESU/CESU) which in turn are
   forwarded to the Provincial Epidemiology and Surveillance Units
   (PESU)



## FIGURE 1C. COMMUNITY QUARANTINE PROTOCOL

Version 05 April 2020 (original)



### FOOTNOTES

Esell-isolation—strict isolation of the patient in a reparate room or area. In the household

Home Quarantine - All members of the household (including pets) must strictly stay at home

### Situations where home quarantine is difficult

- 1. Living with vulnerable person (with comorbids or >60y/o):
- 2. No separate bedroom or bed not >1m away .
- 3: No separate bathroom for patient.
- 4. Not well-ventilated
- 5. No separate utensils and personal things
- 6. No separate towels for handwashing

### the HEAT Menitoring

### Barangay Health Emergency Response Team (BHERT)

- Accomplish a Case Identification Form (CIF)
- Ensure monitoring throughout the duration of isolation & quarantine
- Facilitate home care and basic needs
- A daily report shall be forwarded to the Municipality/City
   Epidemiology and Surveillance Units (MESU/CESU) which in turn are
   forwarded to the Provincial Epidemiology and Surveillance Units
   (FESU)

### Repeat Test Negative

 Two consecutive negative tests 24 hours apart is preferred or at least one negative test prior to discharge

### Improvement of symptoms:

- Temp <37.8°C > 3 days.
- Respiratory symptoms reduced significantly
- OIR shows significant improvement

### Annex H: Package Rate and Rules on Co-pay

a. The applicable package code shall be indicated in the item 9 in CF2.

Package Code	Description
C19CI	COVID-19 Community Isolation Package
C19CIS	Admissions that were referred to the CIU from higher level facilities for step- down care

Table 1: Applicable Package Code

b. The ICD 10 Code in filing for COVID-19 claims shall be in accordance with World Health Organization (WHO) and DOH guidelines. Any further changes by the DOH in the applicable codes shall take precedence and shall be adopted accordingly by PhilHealth.

ICD-10 Code			Description
"Z03.8" "Z20.8"	with	additional code	Patient observed without confirmation or with negative test
"U07.1"			COVID-19 Confirmed

Table 2: Applicable Z codes and ICD-10 codes per DOH DM 2020-0067

- c. The corresponding reimbursement rate is Php 22,449.00 per claim.
- d. The claims from government health care facilities shall be utilized to cover all services, medicines and diagnostics provided for in this Circular and other operating expenses to support delivery of care, including hiring of additional personnel, internet subscription, service provider subscription fee and IT hardware. Any remaining fund may be utilized for incentives for human resource involved in its operation with sharing based on internal guidelines.
- e. For private health care facilities, reimbursements shall be utilized at their discretion, provided that this shall also be used to cover the cost of delivering the services.
- f. Patients shall not be charged out of pocket payment for the services received at the CIU.
- g. CIUs shall AND submit the following reports to their concerned PROs on a monthly basis:
  - i. Expenditure and Utilization Reports (see Annex J)
  - ii. Electronic report (excel file) of admitted patients (see Annex K)



## Annex I: Case Investigation Form



Philippine Integrated Disease Surveillance and Response

### **Case Investigation Form** Coronavirus Disease (COVID-19) Version 9



1) The Case Investigation Form (CIF) is meant to be administered as an interview by a health care worker or any personnel of the DRU. This is not a self-administered questionnaire.

2) Please be advised that DRUs are only allowed to obtain 1 copy of accomplished CIF from a patient.

NO. OR A DIE 1			
s) Please fill out all planks and put a check mark on the appropriat	e box. Never leave an item blan	ik (write N/A). Items with * are required fie	ds. All dates must be in MM/DD/YYYY format

Disease Reporting Unit*		ORU Region and Provinc	e	PhilHealth No.*				
Name of Interviewer		Contact Number of Inter	rviewer	Date of Interview (MM/DD/YYYY)*				
Name of Informant (if applicable)		Relationship - * *		Contact Number of Informant				
,			<u> </u>	Contact Home				
if existing case	th status / outo	come 🗀	Update case classification Update vaccination Update lab result Update chest imaging findings	0	Others, specify:	e / travel history		
			Close Contact			a Case of Close Contact)		
Testing Category/Subgroup* (Check all that a	ipply, refer to Ap	ppendix 2) 🔲 A	<u> В С О D С</u>	] E   D F		<u> </u>		
Part 1. Patient Information				faltig US	Halis Africa (1991)			
1.1. Patient Profile  Last Name*	- · · · · · · · · · · · · · · · · · · ·	irst Name (and Suffix)*	<u> </u>	Middle Name	•	randia and and and an artista		
				<del> </del>		□ Familia		
Birthday (MM/DD/YYYY)*		Age*	<u> </u>	Sex* ☐ Male ☐ Female				
Civil Status		Nationality*						
Occupation		Works in a closed settin		□ No	8 2.24	Unknown		
1.2. Current Address in the Philipping House No./Lot/Bldg.*		itio*				y• × µ b lb l€ a		
110032 110.1/2017 15105.	<u> </u>	. , , , ,	- Durunguy	1 6	- international control of the	<u>, y                                   </u>		
Province 1 9 % and the action and the	Home Phone N	o. (& Area Code)	Cellphone No.	in still	Email Address			
1.3. Permanent Address and Contact House No./Lot/Bidg.	information ( Street/Purok/S			in Cara in the state	Municipality/Cit			
, nouse No./Lot/Blog.	Street/Purok/S		Barangay		wiumicipality/Ci	. <del>y                                    </del>		
Province	Home Phone N	o. (& Area Code)	Celiphone No.	*	Email Address			
1.4. Current Workplace Address and			N Bearing A	· · · · · · · · · · · · · · · · · · ·	No. Cartas and the Men			
Lot/Bldg. 3	Street	's _ v _ a '' · · · · · · ·	Barangay	× ×	Municipality/Cit	<u> </u>		
Province 18 12	Name of Work	place x	Phone No./Cellphone No.	. 6:	Email Address	, v • • <u>x</u>		
1.5. Special Population (indicate furt	hor dotaile on	avancura and traval bi	eta suin Dest 21	_				
		facility:		ion:	<u> </u>	□ No		
Yes, co	ountry of origin		and Passport numbe			□ No		
Returning Overseas Filipino* OFW	: "	OFW 🗆	Non-OFW	_				
<del></del>	ountry of origin		and Passport numbe	r:	_ :	□ No		
■	ity, Municipalit Locally Strand	y, & Province of origin		ana Outsida Basi	dono /Incol T	□ No		
yes in Ves in	stitution type:		and name:	son Outside Resi	dence / cocar rra	□ No .		
I FIAEZ IU CIOZEN ZERNIKZ, I			ommunities, care homes, camps, etc	:.)	<u> </u>	110		
Part 2. Case Investigation Details			- de la lante de la Ciencia de	riá, richt Tara	region to the sales			
2.1. Consultation information				<u> 488 198 - 87</u>				
Have previous COVID-19 related consultation	n? 🗆	Yes, Date of First Cons	sult (MM/DD/YYYY)*			□ No		
Name of facility where first consult was done								
2:2. Disposition at Time of Report*	Provide name	of hospital/isolation/q		di di di	<u> </u>	***************************************		
Admitted in hospital  Admitted in isolation/quarantine facilit			Date and Time admitted in he Date and Time isolated/quara	-				
□ \ In home isolation/quarantine	.y		Date and Time isolated/quara		•	<del>-</del>		
1 1	ged: Date of Di	scharge (MM/DD/YYYY)	, ·	☐ Others:		<del></del>		
Health Status at Consult* (Refer				loderate	□ Severe	☐ Critical		
4. Case Classification* (Refer to App	~	☐ Suspect		onfirmed	☐ Non-COVID-1			
2.5. Vaccination information*								
Dece of vaccination Name of Vaccine	e* Dosé	number (e.g. 1st, 2nd)*	Vaccination center/facility	Region o	of health facility	Adverse event/s?		
لنف		_				☐ Yes ☐ No		
te						☐ Yes ☐ No		

2.6. C	linical Info	rmatio	n					- /*	,						
Date of Onse	t of Illness	(MM/L	אייא/סכ	Y)*		_	C	ICh !!!			-41				
Signs and Syr						_	Comorbidition	es (Check ali	tnat ap	oly IJ presel	nt)				
	tomatic			pnea			□ None			_		Gastro	intestinal		
-	°			rexia				tension					-urin <b>ar</b> y		
Cough				ısea			☐ Diabet						ogical Dise	ase	
l <u> </u>	al weaknes			niting				Disease				Cancer			
□ Fatigue □ Headad				rrhea ered Mental Status				Disease				Others			
☐ Myalgi				osmia (loss of smell, w/c	o anv iden	tified cause)	Pregnant?		☐ Yes	, LMP <i>(MM</i>	I/DD/YYY1	) <u> </u>		_ [	□ No
☐ Sore th				eusia (loss of taste, w/o			High-risk pre	egnancy?	☐ Yes	3			-		No
☐ Coryza				ers, specify		<b>,</b>	Was diagnos	ed to have Se	vere Aci	ite Respirat	ory Illness	? [	□ Yes		No
Chest imaging	g findings s	uggesti	ve of C	OVID-19			!		•			.—!—			
Date done	Chest ima			Results	_							_			
	☐ Chest		raphy	☐ Normal ☐ C	hest radio	graphy: Hazy o	pacities, often	rounded in	morpho	logy, with p	periphera	l and l	ower lung o	fist.	
	☐ Chest			_		-	al ground glass						•		_
	Lung	ultrasou	ınd				d pleural lines	, B lines, con	rsolidati	ve patterns	with or v	withou	t air broncl	nogram	S
	│□ None				ther findir	gs, specify									
	boratory														
Have tested p		ng L		, date of specimen Colle	ection (MN	1/DD/YYYY) <b>*</b> _							□ N	0	
RT-PCR before		_		oratory*				No. o	f previo	ıs RT-PCR s	wabs do	ne			
Date collected	d* Date r	eleased	Lat	oratory*		pe of test*						Resu			
						RT-PCR (OF	•	_					Pending		Negative
	ĺ		ŀ			•	•	prand o Antibod					Positive		Equivocal
						•	3 6110 1413)		iy iest			' '	Others:		
·-			$\dashv$				PS) [	Antigen	: reason				Pending		Negative
					[		•	brand o					Positive		Equivocal
						RT-PCR (OF	S and NPS) E	☐ Antibod	ly Test				Others:	_	<b>-</b> 4
						Others:									
2.8. O	utcome/C	onditio	n at Tin	ne of Report*				-							
☐ Active (cur	rrently adr	nitted/i	isolatio	n/quarantine) 🗆 Rec	overed, d	ate of recover	y (MM/DD/YYYY)*			🗆 Died, da	te of deat	th /MM	/00/YYYY)* _		
<u> </u>		Imma	diate C		. <u>.</u> .			Anteceden	+ Cours			-			
If died,		-	utate C												
cause of deat	n*	Under	lying C	ause:				Contributo	ry Cond	itions:					
														J. C.	
				d Travel History						<del></del>				**************************************	
				e and/or confirmed CO					date of	last contac	t (MM/DI	D/YYYY,	)*		_
of signs and s	ymptoms?	OR II	Asympt	omatic, 14 days before	swabbing	or specimen c	ollection? *	□ No			□ Un	knowr	1		
1.				known COVID-19 trans		•		1 .	Interna	tional	□ Ye	s, Loca	ıl		
signs and sym	nptoms? O	R If Asy	mptom	atic, 14 days before sw				□ No			□ Un	know	n exposure		
If Internation	al Travel,					ve travel date:		*		From:			To:		
country of ori	igin	_			With o	ngoing COVID	-19 communit	y transmissio	on?	☐ Yes			□ No		
Airline/Sea ve	essel			Flight/Vessel Number			Date of depart	arture (MM/	'סס/ץץץץץ	)	Date of	arrival	in PH (MM	/DD/YY	YY)
											ļ				
If Local Travel	I, specify to	avel pla	aces (Ci	heck all that apply, prov	ide name	of facility, add	ress, and inclu	sive travel de	ates in N	/M/DD/YYY	γ)				
Place Visited							Address			Inclusive Tr		es	With or	ngoing	COVID-19
Place Visited				Name of Place		(Region, Pr	ovince, Munici	pality/City)	From	1:	To:		Commun	ity Tra	nsmission?
☐ Health I	Facility		(						Í				☐ Yes		□ No
☐ Closed :	Settings		<del>                                     </del>			_							☐ Yes		□ No
☐ School			-							-			☐ Yes		No
					<del></del> -								ļ		
☐ Workpl		_											☐ Yes		□ No
☐ Market	:		L _										☐ Yes		□ No
☐ Social G	Sathering			<u> </u>									☐ Yes		□ No
☐ Others							<u> </u>						☐ Yes		□ No
☐ Transpo	ort Service,	specify	the fo	llowing:									<u> </u>		
Airline / Sea v				light / Vessel / Bus No.	Plac	e of Origin	Departure I	Date (MM/DI	DAYYYI	Des	tination		Date of Arr	ival (MI	U/DD/YYYY)
, , , , , , , , , , , , , , , , , , ,			-	iight/ receif accited		0.00	Беринане.		-,,,,,				Date 017111	1001   1011	.,, 55, , , , , , ,
							<del> </del>								
										<u> </u>					
16 m						Name (Us	e the back pag	e if needed)			Co	ntact l	Number		
1 ' ' 1.				contact numbers of personners of personners until t											
1	e pauent ()	-	,	contact numbers of pe									_		
L- II asvmnime	ratic, provi	ge nam	ies ann												
were with	a patient o	1.													_
	a patient o	1.		imen was submitted fo											

#### SUSPECT

- A) A person who meets the clinical AND epidemiological criteria
  - Clinical criteria:
    - 1) Acute onset of fever AND cough OR
    - Acute onset of ANY THREE OR MORE of the following signs or symptoms; fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia / nausea/vomiting, diarrhea, altered mental status. AND
  - Epidemiological criteria
    - Residing/working in an area with high risk of transmission of the virus (e.g. closed residential settings and humanitarian settings, such as camp and camp-like setting for displaced persons), any time w/in the 14 days prior to symptoms onset OR
    - Residing in or travel to an area with community transmission anytime w/in the 14 days prior to symptoms onset; OR
    - Working in health setting, including w/in the health facilities and w/in households, anytime w/in the 14 days prior to symptom onset;

      OR
- B) A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of ≥ 38°C; cough with onset w/in the last 10 days; and who requires hospitalization)

#### PROBABLE

- A) A patient who meets the clinical criteria (on the left) AND is contact of a probable or confirmed case, or epidemiologically linked to a cluster of cases which had had at least one confirmed identified within that cluster
- B) A suspect case (on the left) with chest imaging showing findings suggestive of COVID-19 disease. Typical chest imaging findings include (Manna, 2020):
  - Chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution
  - Chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral
    and lower lung distribution
  - Lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative
    patterns with or without air bronchograms
- C) A person with recent onset of anosmía (loss of smell), ageusia (loss of taste) in the absence of any other identified cause
- D) Death, not otherwise explained, in an adult with respiratory distress preceding death AND who was a contact of a probable or confirmed case or epidemiologically linked to a cluster which has had at least one confirmed case identified with that cluster

#### CONFIRMED

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

#### Appendix 2. Testing Category / Subgroup

- A Individuals with severe/critical symptoms and relevant history of travel/contact
- Individuals with mild symptoms, relevant history of travel/contact, and considered vulnerable; vulnerable populations include those elderly and with preexisting medical conditions that predispose them to severe presentation and complications of COVID-19
- C Individuals with mild symptoms, and relevant history of travel and/or contact
  - Individuals with no symptoms but with relevant history of travel and/or contact or high risk of
- D exposure. These include:
- 1 Contact-traced Individuals
- D2 Healthcare workers, who shall be prioritized for regular testing in order to ensure the stability of our healthcare system
- D3 Returning Overseas Filipino (ROF) workers, who shall immediately be tested at port of entry
- Filiplno citizens in a specific locality within the Philippines who have expressed intention to
   return to their place of residence/home origin (Locally Stranded Individuals) may be tested subject to the existing protocols of the IATF
- E Frontliners Indirectly involved in health care provision in the response against COVID-19 may be tested as follows:
- E1 Those with high or direct exposure to COVID-19 regardless of location may be tested up to once a week. These include: (1) Personnel manning the Temporary Treatment and Quarantine Facilities (LGU and Nationally-managed); (2) Personnel serving at the COVID-19 swabbing center; (3) Contact tracing personnel; and (4) Any personnel conducting swabbing for COVID-19 testing
- Those who do not have high or direct exposure to COVID-19 but who live or work in Special Concern Areas may be tested up to every two to four weeks. These include the following: (1) Personnel manning Quarantine Control Points, including those from Armed Forces of the Philippines, Bureau of Fire Protection; (2) National / Regional / Local Risk Reduction and Management Teams; (3) Officials from any local government / city / municipality health office (CEDSU, CESU, etc.); (4) Barangay Health Emergency Response Teams and barangay officials providing barangay border control and performing COVID-19-related tasks; (5) Personnel of Bureau of Corrections and Bureau of Jail Penology & Management; (6) Personnel manning the One-Stop-Shop in the Management of RÖFs; (7) Border control or patrol officers; such the Philippine Coast Guard; and (8) Social workers providing amelioration and relief assistance to communities and performing COVID-19-related tasks
- Other vulnerable patients and those living in confined spaces. These include but are not limited to: (1) Pregnant patients who shall be tested during the peripartum period; (2) Dialysis patients; (3) Patients who are immunocompromised, such as those who have HIV/AIDS, inherited diseases that affect the immune system; (4) Patients undergoing chemotherapy or radiotherapy; (5) Patients who will undergo elective surgical procedures with high risk for transmission; (6) Any person who have had organ transplants, or have had bone marrow or stem cell transplant in the past 6 months; (7) Any person who is about to be admitted in enclosed institutions such as jails, penitentiaries, and mental institutions.

- G Residents, occupants or workers in a localized area with an active COVID-19 cluster, as identified and declared by the local chief executive in accordance with existing DOH Guidelines and consistent with the National Task Force Memorandum Circular No. 02 s.2020 or the Operational Guidelines on the Application of the Zoning Containment Strategy in the Localization of the National Action Plan Against COVID-19 Response. The local chief executive shall conduct the necessary testing in order to protect the broader community and critical economic activities and to avoid a declaration of a wider community quarantine.
- H Frontliners in Tourist Zones:
- All workers and employees in the hospitality and tourism sectors in El Nido, Boracay, Coron, Panglao, Siargao and other tourist zones, as Identified and declared by the Department of Tourism. These workers and employees may be tested once every four (4) weeks.
- H2 All travelers, whether of domestic or foreign origin, may be tested at least once, at their own expense, prior to entry into any designated tourist zone, as identified and declared by the Department of Tourism.
- All workers and employees of manufacturing companies and public service providers registered in economic zones located in Special Concern Areas may be tested regularly.
  - Economy Workers
- J1 Frontline and Economic Priority Workers, defined as those 1) who work in high priority sectors, both public and private, 2) have high interaction with and exposure to the public, and 3) who live or work in Special Concerns Areas, may be tested every three (3) months: These include but not limited to:
  - Transport and Logistics: drivers of taxis, ride hailing services, buses, public transport vehicle, conductors, pilots, flight attendants, flight engineers, rail operators, mechanics, servicemen, delivery staff, water transport workers (ferries, inter-island shipping, ports)
  - Food Retails: waiters, waitress, bar attendants, baristas, cheis, cooks, restaurant managers
     Education: teachers at all levels of education and other school frontliners such as guidance counselors, librarians, cashiers
  - → Financial Services: bank tellers
  - Non-Food Retails: cashiers, stock clerks, retail salespersons
  - Services: hairdressers, barbers, manicurists, pedicurists, massage therapists, embalmers, morticians, undertakers, funeral directors, parking lot attendants, security guards, messengers
  - Construction: construction workers including carpenters, stonemasons, electricians, painters, foremen, supervisors, civil engineers, structural engineers, construction managers, crane/tower operators, elevator installers, repairmen
  - Water Supply, Sewerage, Waster Management: plumbers, recycling/ reclamation workers, garbage collectors, water/wastewater engineers, janitors, cleaners
  - Public Sector: judges, courtroom clerks, staff and security; all national and local government employees rendering frontline services in special concern areas
  - Mass Media: field reporters, photographers, cameramen
- All employees not covered above are not required to undergo testing but are encouraged to be tested every quarter. Private sector employers are highly encouraged to send their employees for regular testing at the employers' expense
  - in order to avoid lockdowns that may do more damage to their companies

#### Appendix 3. Severity of the Disease

#### MILD

Symptomatic patients presenting with fever, cough, fatigue, anorexia, myalgias; other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting; loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms with NO signs of pneumonia or hypoxia

#### MODERATE

- Adolescent or adult with clinical signs of non-severe pneumonia (e.g. fever, cough, dyspnea, respiratory rate (RR) = 21-30 breaths/minute, peripheral capillary oxygen saturation (SpO2) >92% on room air)
- Child with clinical signs of non-severe pneumonia (cough or difficulty of breathing and fast breathing [ < 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40] and/or chest indrawing)

#### SEVERE

- Adolescent or adult with clinical signs of severe pneumonia or severe acute respiratory infection as follows: fever, cough, dyspnea, RR>30 breaths/minute, source respiratory distress or SpO2 < 92% on room air</li>
- solere respiratory distress or SpO2 < 92% on room air

  2. Child with clinical signs of pneumonia (cough or difficulty in breathing) plus at least one of the following:
- Central cyanosis or SpO2 < 90%; severe respiratory distress (e.g. fast breathling, grunting, very severe chest indrawing); general danger sign:
  Inability to breastfeed or drink, lethargy or unconsciousness, or convulsions.

  b. East breathing (in breaths/min): < 2 months: > 60; 2-11 months: > 50; 1-5

### CRITICAL

Patients manifesting with acute respiratory distress syndrome, sepsis and/or septic shock:

- 1. Acute Respiratory Distress Syndrome (ARDS)
  - Patients with onset within 1 week of known clinical insult (pneumonia) or new or worsening respiratory
    symptoms, progressing infiltrates on chest X-ray or chest CT scan, with respiratory failure not fully
    explained by cardiac failure or fluid overload
- 2. Sepsis
  - a. Adults with life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction include altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia
  - b. Children with suspected or proven infection and > 2 age-based systemic inflammatory response syndrome criteria (abnormal temperature [> 38.5 °C or < 36 °C); tachycardia for age or bradycardia for age if < 1year; tachypnea for age or need for mechanical ventilation; abnormal white blood cell count for age or > 10% bands), of which one must be abnormal temperature or white blood cell count.
- 3. Septic Shock
  - Adults with persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP > 65 mmHg and serum lactate level >2mmol/L
  - i. Children with any hypotension (SBP < Sth centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in Infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia.

Monthly Expense Report	
	Amount
Amount spent on personnel salaries and wages	
Amount spent on benefits for employees	-
Allowances provided to employees at this facility	
Total amount spent on Personnel Services	
Amount spent on medicines (Revolving fund &	
National Government)	
Amount spent of medical supplies (i.e. consumables)	
Amount spent on laboratory and imaging tests	
Amount spent on utilities	
Amount spent on non-medical services (e.g. food	-
supply, security, waste management, laundry, fuel)	
Total Amount spent on maintenance and other	
operating expense	
Amount spent on infrastructure (e.g. installation of	
ramps, tents, etc)	
Amount spent on equipment (e.g ECG, X-ray)	
Total Amount of Capital Outlay	
Total Expenditure	

NOTE: Please email to your concerned PhilHealth Regional Office (PRO).

	CERTIFIED BY:
	GIU
Œ,	CIU Manager Signature over printed name and designation
STE	ted
\$ O	Date Signed:

### Annex K: List of Admitted Patients

PIN	Patient Name (Last, First and Middle Name)	Membership Category (Member or Dependent)	Date of Birth (mm/dd/yyyy)	Address	Date of Admission (mm/dd/yyyy)	Date of Discharge (mm/dd/yyy	
					-		
					-		
				_		i	

NOTE: Please email to your concerned PhilHealth Regional Office (PRO).

Page 1 of 1 of Annex K

